IRTC Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of -19.35% compared to iRhythm Technologies's net margin of 30.99%. iRhythm Technologies's return on equity of -112.03% beat Intuitive Surgical's return on equity of 15.82%.

iRhythm Technologies has a consensus price target of $141.33, signalling downside risk potential of -4.17%. On the other hand Intuitive Surgical has an analysts' consensus of $578.17 which suggests that it could grow by 9.89%. Given that Intuitive Surgical has higher upside potential than iRhythm Technologies, analysts believe Intuitive Surgical is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.402, which suggesting that the stock is 40.168% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.875%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. iRhythm Technologies's net income of -$30.7M is lower than Intuitive Surgical's net income of $698.4M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 77.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.47x versus 21.92x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -19.35% compared to iRhythm Technologies's net margin of -45.89%. iRhythm Technologies's return on equity of -112.03% beat Masimo's return on equity of -39.91%.

iRhythm Technologies has a consensus price target of $141.33, signalling downside risk potential of -4.17%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 5.93%. Given that Masimo has higher upside potential than iRhythm Technologies, analysts believe Masimo is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.402, which suggesting that the stock is 40.168% more volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.725%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Masimo quarterly revenues of $372M. iRhythm Technologies's net income of -$30.7M is higher than Masimo's net income of -$170.7M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.47x versus 4.72x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -19.35% compared to iRhythm Technologies's net margin of 6.22%. iRhythm Technologies's return on equity of -112.03% beat Insulet's return on equity of 36.9%.

iRhythm Technologies has a consensus price target of $141.33, signalling downside risk potential of -4.17%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.52%. Given that Insulet has higher upside potential than iRhythm Technologies, analysts believe Insulet is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.402, which suggesting that the stock is 40.168% more volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Insulet quarterly revenues of $569M. iRhythm Technologies's net income of -$30.7M is lower than Insulet's net income of $35.4M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Insulet's PE ratio is 54.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.47x versus 10.28x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -19.35% compared to iRhythm Technologies's net margin of 28.26%. iRhythm Technologies's return on equity of -112.03% beat ResMed's return on equity of 25.76%.

iRhythm Technologies has a consensus price target of $141.33, signalling downside risk potential of -4.17%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 5.38%. Given that ResMed has higher upside potential than iRhythm Technologies, analysts believe ResMed is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.402, which suggesting that the stock is 40.168% more volatile than S&P 500. In comparison ResMed has a beta of 0.778, suggesting its less volatile than the S&P 500 by 22.169%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.85% to investors and pays a quarterly dividend of $0.53 per share. iRhythm Technologies pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

iRhythm Technologies quarterly revenues are $158.7M, which are smaller than ResMed quarterly revenues of $1.3B. iRhythm Technologies's net income of -$30.7M is lower than ResMed's net income of $365M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while ResMed's PE ratio is 28.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.47x versus 7.37x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.